3-5 years of experience
Concerned about your lack of experience? Learn More...
Employment Type:
Full time
Job Category:
See more jobs for students and recent grads who studied:
Analyst III, Materials
Biogen | Research Triangle Park, North Carolina
Tell Us More About Your Job Preferences
By telling us what you think of this job, we can help find jobs that match your interests. If you want to see more jobs like this, click on the smiley face. Or if this job isn't what you are looking for, click the frowny face. Learn More...

Follow This Company

Job Description

External Posting TitleAnalyst III, Materials
Job DescriptionThe incumbent leads all manufacturing planning and purchasing raw materials required to support the RTP Manufacturing Site. The incumbent is also responsible for supporting the monitoring of the manufacturing schedule and raw material inventory. The incumbent collaborates daily with manufacturing, warehouse operations, Quality Control, and Quality to resolve raw material issues, scheduling conflicts, inventory levels, and delivery requirements. He issues the monthly retest/expired material report and holds monthly meetings to ensure raw materials are released to support manufacturing planned demand. The incumbent has a working knowledge of Oracle and/or SAP ERP systems and manufacturing supply chain experience. He is responsible for formula/recipe creation and master data creation/enrichment in Oracle, as well as the creation/reconciliation of production batches as needed. The incumbent is also responsible for monitoring and tracking raw material usage and inventory levels, excel and obsolete analysis and forecasting, end of month report review, cycle count schedule creation, entering and completing raw material/API/Finished product cycle counts, and participating in tech transfers and bill of material development/maintenance.

Principal Accountabilities:
1. Review production schedules daily to coordinate manufacturing needs with the warehouse and dispensary to determine production activities that require entry/updating in OPM; Also responsible for raw materials planning and inventory control activities (for raw materials and WIP inventory), including forecasted demand maintenance, safety stock/ROP levels, and the weekly management of ASCP purchasing suggestions.
2. Responsible for tactical day-to-day raw material planning and inventory control activities including creation and allocation of raw material to batches for raw material movement and dispensing. Responsible for ensuring timely and accurate reconciliation of batches in OPM. Interacts with manufacturing to complete month end closing activities.
3. Revises and maintains SOPs, SLRs, Formulas, Recipes, Validity Rules, Production Rules, Warehouse Rules in OPM. Supports new item creation process and Master Data enrichment. Initiates and post weekly cycle counts and investigates discrepancies as needed.
4. Responsible for reviewing raw material vendor change notifications for inventory impact and facilitation of cross-functions discussions, as required, to drive changes to closure and/or visibility of change or inventory impact.
5. Supports tech transfers and the development/maintenance of manufacturing bills of materials, as needed, and ensures that the raw materials are procured and on-hand to support the manufacturing schedule. Analyzes data and creates the Expired and Obsolete report at pre-determined frequency.

LocationResearch Triangle Park, NC, US
Job CategorySupply Chain, Global Operations
Requisition Number31974BR
QualificationsMinimum 2 year of relevant experience and/or training in a GMP regulated industry or an equivalent combination of education and experience.
EducationMinimum Bachelor's degree in Chemical/Biochemical Engineering, Supply Chain Management, or other related business/science/technical field or High School Diploma with relevant years of experience
About BiogenCorporate Overview

Through cutting-edge science and medicine, Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases. Biogen is a pioneer in biotechnology and today the Company has the leading portfolio of medicines to treat multiple sclerosis (MS), has introduced the first and only approved treatment for spinal muscular atrophy, and is at the forefront of neurology research for conditions including Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis (ALS). Biogen also manufactures and commercializes biosimilars of advanced biologics. Our global organization of nearly 7,000 employees is committed to a single mission: making a meaningful difference in the lives of patients with few or no treatment options.

One of the pioneers in biotechnology, Biogen was founded in 1978 and today serves patients in nearly 90 countries. Our global headquarters and R&D operations are located in Cambridge, Massachusetts, with an international headquarters in Zug, Switzerland, world-class manufacturing facilities in Research Triangle Park, North Carolina, USA and Hillerod, Denmark, and affiliate locations around the world.

Our Science

We aspire to have the greatest impact on patients and science of any biotechnology company in the history of our industry. To us, that means creating novel medicines that benefit individuals and society, and bringing new scientific understanding to diseases for which there are no adequate treatments.

For nearly two decades Biogen has led in the research and development of new therapies to treat MS, including the most prescribed oral treatment in the world. Now our research is driving revolutionary new MS treatments with the goal of reversing or even repairing damage caused by the disease. We are now applying our neurological expertise to solve some of most challenging and complex diseases of the brain, including Alzheimer's disease, Parkinson's disease, and ALS. As we uncover new insights into human biology, Biogen is employing cutting-edge technologies to discover potential treatments for rare and genetic disorders.

Biogen is revolutionizing biologics manufacturing, developing the industry's most advanced plants and processes. This expertise is used to produce both original innovative therapies and biosimilars that expand patient access to lower-cost medicines.

Our Corporate Citizenship

The same intellectual discipline and passion that drives our science is reflected in our corporate citizenship, environmental sustainability, and commitment to diversity and inclusion. As a company, we are focused on improving science education and limiting the impact of our company on the environment. In 2015, we became a carbon neutral company and ranked first place on Newsweek's 2015 Green Rankings, and we are an industry leader on the Dow Jones Sustainability World Index. Biogen was named to Science's list of Top Employers of 2015 and in 2017 received a perfect score of 100 for the fourth consecutive year on the Human Rights Campaign (HRC) Corporate Equality Index, which also named Biogen as one of its Best Places to Work.

All qualified applicants will receive consideration for employment without regard to sex, gender identity or expression, sexual orientation, marital status, race, color, national origin, ancestry, ethnicity, religion, age, veteran status, disability, genetic information or any other basis protected by federal, state or local law. Biogen is an E-Verify Employer in the United States.

Please be advised that all legitimate correspondence from a Biogen employee will come from "@biogen.com" email accounts.

About Biogen

Biogen Idec Inc. is engaged in the development, manufacturing, and commercialization of therapies. The Company's products address diseases such as multiple sclerosis, lymphoma and rheumatoid arthritis. The Company has four products: AVONEX (interferon beta-1a), RITUXAN (rituximab), TYSABRI (natalizumab) and FUMADERM (dimethylfumarate and monoethylfumarate salts). AVONEX is used in the treatment of relapsing forms of multiple sclerosis (MS). RITUXAN is used in the treatment of relapsed or refractory low-grade or follicular, CD20-positive, and B-cell, non-Hodgkin's lymphomas (B-cell NHLs). TYSABRI is approved for the treatment of relapsing forms of MS. FUMADERM acts as an immunomudulator. It also has product candidates, such as BG-12 (acquired with the purchase of Fumapharm), ANTI-CD80 antibody/(galiximab), ANTI-CD23 antibody/(lumiliximab), Ocrelizumab/(Humanized ANTI-CD20 Antibody) and Lixivaptan.In January 2007, the Company completed the acquisition of Syntonix Pharmaceuticals, Inc. (Source: 10-K)

This company profile was created by AfterCollege and is about Biogen. This page is not endorsed by or affiliated with Biogen. For questions regarding company profiles, please email: care@aftercollege.com.